




Mortality and morbidity of major congenital heart disease related to general prenatal
screening for malformations
Lytzen, Rebekka; Vejlstrup, Niels; Bjerre, Jesper; Petersen, Olav Bjørn; Leenskjold, Stine;
Dodd, James Keith; Jørgensen, Finn Stener; Søndergaard, Lars
Published in:
International Journal of Cardiology







Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Lytzen, R., Vejlstrup, N., Bjerre, J., Petersen, O. B., Leenskjold, S., Dodd, J. K., Jørgensen, F. S., &
Søndergaard, L. (2019). Mortality and morbidity of major congenital heart disease related to general prenatal
screening for malformations. International Journal of Cardiology, 290, 93-99.
https://doi.org/10.1016/j.ijcard.2019.05.017
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Accepted Manuscript
Mortality and morbidity of major congenital heart disease related
to general prenatal screening for malformations
Rebekka Lytzen, Niels Vejlstrup, Jesper Bjerre, Olav Bjørn





To appear in: International Journal of Cardiology
Received date: 29 October 2018
Revised date: 3 April 2019
Accepted date: 5 May 2019
Please cite this article as: R. Lytzen, N. Vejlstrup, J. Bjerre, et al., Mortality and morbidity
of major congenital heart disease related to general prenatal screening for malformations,
International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.05.017
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may

















Mortality and morbidity of major congenital heart disease related to general prenatal 
screening for malformations. 
Rebekka Lytzen, M.D.
 1
, Niels Vejlstrup, M.D., PhD
2
, Jesper Bjerre, M.D.
3
, Olav Bjørn 
Petersen, M.D.,
4
, Stine Leenskjold, M.D.
5
, James Keith Dodd, M.D.
6
, Finn Stener Jørgensen, 
D.M.Sc
7
, Lars Søndergaard, Prof., D.M.Sc.
 8 
1. Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns Alle 7, 
2100 Copenhagen O, Denmark. E-mail: rebekka@tondering.dk. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 
2. Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns Alle 7, 
2100 Copenhagen O, Denmark. E-mail: Niels.Vejlstrup@regionh.dk. This author takes responsibility 
for all aspects of the reliability and freedom from bias of the data presented and their discussed 
interpretation. 
3. Department of Paediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus 
N, Denmark. E-mail: jesper.bjerre@skejby.rm.dk. This author takes responsibility for all aspects of the 
reliability and freedom from bias of the data presented and their discussed interpretation. 
4. Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Aarhus University Hospital, , Palle 
Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.  E-mail: olavpete@rm.dk. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. 
5. Department of Obstetrics and Gynaecology, Aalborg University Hospital, Reberbansgade 15, 9000 
Aalborg, Denmark. E-mail: slo@rn.dk. This author takes responsibility for all aspects of the reliability 
and freedom from bias of the data presented and their discussed interpretation. 
6. Department of Paediatrics, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, 2650 
Hvidovre, Denmark. E-mail: james.keith.dodd.01@regionh.dk. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 
7. Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Copenhagen University Hospital 

















This author takes responsibility for all aspects of the reliability and freedom from bias of the data 
presented and their discussed interpretation. 
8. Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns Alle 7, 
2100 Copenhagen O, Denmark. E-mail: Lars.Soendergaard.01@regionh.dk. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. 
  
Corresponding author:  
Rebekka Lytzen 
Department of Cardiology, section 2013 
Inge Lehmanns vej 7 
2100 Copenhagen 
Denmark.  
Email: rebekka@tondering.dk  
Phone: +45 26 28 83 24, Fax: +45 35 45 27 05  
 
Sources of founding 
The work was supported by the Danish Heart Foundation [grants 14-R97-A5001-26024, 15-
R98-A5047-26032, 16-R99-A5067-26039]; Ville Heise’s Legat [grant M20-16]; Johannes 
Fog’s Fond; Kong Christian den Tiendes Fond [grant 70/16]; and Snedkermester Sophus 
Jacobsen og hustru Astrid Jacobsen’s Fond 
 









































Major congenital heart diseases (CHD) often demand intervention in the 
neonatal period. Prenatal diagnosis may improve mortality by eliminating the diagnostic 
delay; however, there is controversy concerning its true effect.  
We aimed to evaluate the effect of general prenatal screening on prognosis by 
comparing a period without general prenatal screening to a period with general prenatal 
screening. 
Methods  
We conducted a nationwide retrospective study including live born children and 
terminated fetuses diagnosed with major CHD. Prenatal screening was recommended only in 
high risk pregnancies between 1996 and 2004, whereas general prenatal screening was 
recommended between 2005 and 2013. We assessed the influence of general prenatal 
screening on all-cause mortality, cardiac death, preoperative and postoperative 30-day 
mortality and complication rate.  
Results 
1-year mortality decreased over both periods, but the decrease was greater in the 
screening period (Odds ratio 0.92 (CI 0.83-1.00), p=0.047). Prenatal detection of major CHD 
was associated with cardiac death in the period without general screening (Hazard Ratio 2.40 
(CI 1.72-3.33), p<0.001), whereas there was no significant association once general screening 

















postoperative mortality found in the period without general screening was insignificant after 
the implementation of general screening.  
Conclusion 
Mortality in major CHD decreased throughout the study, especially in the period 
with general prenatal screening. However, comparing a prenatally diagnosed group with a 



















AVSD: Atrioventricular septal defect 
ccTGA: Congenitally corrected transposition of the great arteries 
CHD: Congenital heart disease 
CI: Confidence Interval 
CoA: Coarctation of the aorta 
DORV: Double outlet right ventricle 
HR: Hazard Ratio 
IAA: Interrupted aortic arch 
ICD: International Classification of Disease 
IQR: Interquartile Range 
LOS: Length of stay 
OR: Odds Ratio 
PA-IVS: Pulmonary atresia with intact ventricular septum 
PA-VSD: Pulmonary atresia with ventricular septal defect 
TGA: Transposition of the great arteries 
TOF: Tetralogy of Fallot 
TOP: Termination of pregnancy 



















Congenital heart disease (CHD) comprises a wide variety of defects with 
diversity in complexity and prognosis, where major CHD typically requires intervention 
within the first year of life. Early diagnosis is crucial as some major CHD demand surgical or 
catheter-based intervention in the neonatal period. However, postnatal diagnosis is not always 
straightforward and may be delayed due to late presentation, misinterpretation and delayed 
referral. 
Prenatal diagnosis eliminates the diagnostic delay, permits delivery at a tertiary 
centre specialised in the management of major CHD, thus enabling early invasive treatment. It 
is controversial whether prenatal diagnosis improves the prognosis of the child
1-17
.  In fact, 
newborns with a prenatal diagnosis of a CHD have repeatedly been shown to have higher 
mortality than expected despite measures taken to optimise perinatal treatment
1-3,7
. However, 
a spectrum of severity exists across as well as within the individual defects, and comparing 
major CHD diagnosed prenatally with those diagnosed postnatally may result in selection 
bias
5
. Few studies consider this weakness when assessing the effect of prenatal screening.  
Duct dependent circulation can lead to compromised oxygenation of organs, and 
the immaturity of certain end-organs makes infants more susceptible
18
. However, 
investigations on the effect of prenatal diagnosis on these complications are lacking.  
In Denmark, the strategy for prenatal screening for congenital malformations 
was changed in 2004 and currently all pregnant women are offered two ultrasonic scans. By 
comparing a period without nationwide general prenatal screening with a period when general 

















on mortality and morbidity in prenatally diagnosed children with major CHD, hypothesising 
that general prenatal screening improves survival and decreases postnatal complications.  
 
2.1. 
Material and Methods 
This nationwide study included all live born children and terminated 
pregnancies (TOP) with major CHD from 1996 to 2013. All Danish residents are given a 
unique registration number at birth, thus enabling individual identification of every person 
with relevant diagnoses. In January 2015, data were extracted from the Danish National 
Patient Registry, which is a nationwide, population-based registry carrying records of all 
outpatient visits and hospital admissions, and the Cause of Death Registry, which 
prospectively records all causes of death.  
2.1.1 
Screening procedure 
Between 1996 and 2004 the Danish Health Authority only recommended 
prenatal investigations in high risk pregnancies, defined by age, medical history, family 
history and objective findings. In 2004, the recommendations were changed and from 2005-
2013 two ultrasounds were offered to all pregnant women; one to assess the nuchal fold and 
determine the risk of aneuploidy at 11-13 weeks, and a malformation scan at 18-20 weeks of 
gestation
19
. This examination includes cardiac evaluation: The four-chamber view has been 
used throughout the period and the three-vessel and outflow-tract views were fully 

















If at any time a CHD was suspected, the woman was referred to a tertiary centre 
for fetal echocardiography by a specialist in fetal medicine. If a major CHD was confirmed, 
the parents could apply for TOP or continue the pregnancy. If the diagnosed CHD was 
deemed to necessitate medical or surgical treatment shortly after birth, delivery was set to take 
place at a tertiary centre.  
2.1.2 
Patients born with a CHD 
The National Patient Registry was used to identify patients, who at any time had 
been given an International Classification of Disease (ICD)-10 code corresponding to a CHD 
(ICD-10 code DQ20-DQ25). Extracted data included local hospital, place of birth, admission 
days in the first year of life, as well as all procedural and ICD-10 codes given.  
Major CHD was defined as morphologically complex malformations of the 
heart and great arteries that usually necessitate intervention within the first year of life
2,20
. 
Included diagnoses consisted (in hierarchical order modified from Allan et al.
21
) of: 1) 
Univentricular heart, 2) Congenitally corrected transposition of the great arteries, 3) Truncus 
arteriosus, 4) Transposition of the great arteries, 5) Interrupted aortic arch, 6) Atrioventricular 
septal defects, 7) Double outlet right ventricle, 8) Coarctation of the aorta, 9) Ebstein’s 
anomaly, 10) Pulmonary atresia with ventricular septal defect, 11) Pulmonary atresia with 
intact ventricular septum and 12) Tetralogy of Fallot.  
Patient records for children with possible major CHD, based on ICD-10 code, 
surgical or catheter-based intervention within the first year of life or if the child had died, 
were examined to validate all CHD codes. Only patients with an ICD-10 code corresponding 

















been made prenatally. If so, we evaluated the prenatal investigations and documented the 
findings. Only diagnoses verified postnatally or at autopsy were included.  
2.1.3. 
TOP due to a CHD 
ICD-10 codes regarding TOP after 12 weeks of gestation (DO04.0-DO07.9) 
were used to identify possible TOPs due to a CHD in the fetus. Data (date and place of TOP, 
all ICD-10 codes connected to the TOP, and gestation age at TOP) were extracted from the 
National Patient Registry and the Registry of Abortions. We reviewed patient records and 
included cases where the fetus was found to have a CHD.  
2.1.4. 
Definitions 
Non-cardiovascular malformation was defined as an ICD-10 code describing a 
congenital malformation other than a CHD (DQ00-DQ19 and DQ26-DQ89). As 
recommended by the European Surveillance of Congenital Anomalies
22
, isolated minor 
anomalies were excluded.  
Length of stay (LOS) was defined as total number of hospital admission days in 
the first year of life, and morbidity was defined as the occurrence of complications, i.e. 
necrotizing enterocolitis, intracerebral haemorrhage, cerebral palsy, mental retardation, 
seizures, heart failure, liver failure or acute kidney injury. 
Denmark has three tertiary centres for the management of CHD and 49 referral 
hospitals. Distance from a referral hospital to a tertiary centre was measured as the shortest 



















Categorical data are presented as percentages and 95% confidence intervals 
(CI). Continuous data are given as median with interquartile range (IQR). χ
2
-analysis and 
Fisher’s exact test were used to test for differences in categorical probabilities. Logistic 
regression analysis was applied when adjusting for confounders and assessing differences in 
continuous data. Splines were applied to allow analyses of the temporal changes before and 
after the introduction of general prenatal screening by comparing estimates before and after 
2004. Estimates are given as Odds Ratio (OR).  
Cox regression analysis was used when evaluating differences in survival. The 
non-screening period and the screening period were assessed separately and compared for 
temporal differences. We tested for linearity, interactions, and proportionality, using 
Schoenfeld residuals, and the assumptions for Cox regression analysis were met for all 
covariates. Survival analyses were performed individually on the major CHD diagnoses, 
except when event count was less than 2. Cause of death was categorised into “Cardiac death” 
and “Non-cardiac death”, corresponding to the diagnosis on the death certificate. Cause 
specific cox regression was used to assess the effect of prenatal diagnosis on the hazard of 
cardiac death. All survival analyses were adjusted for non-cardiovascular malformation, 
chromosomal anomaly, sex and prematurity. 
Survival analyses were performed using R-package for Windows, version 3.2.3. 
All other analyses were made in Statistical Analysis Software version 9.4. A p-value under 

















analysing the individual diseases separately, p-values were adjusted using Bonferroni 
correction, with 13 hypotheses tested. 
2.1.6. 
Declaration of Helsinki 
This study complies with the Declaration of Helsinki, and has been approved by 
the Danish Data Protection Agency (jr.no 2014-41-2943). The study is a registry research 





2,224 live born children and 471 terminated pregnancies with major CHD were 
included in the study. Follow-up for live born children was median 8.5 years (IQR 2.3-13.8). 
Among all live born children, 15.5% were prenatally diagnosed and 93.0% (CI 90.3-95.7) of 
these children were delivered at tertiary centres. For children born at a referral hospital, the 
median distance to a tertiary centre was 65 kilometres (IQR 16-104 kilometres). Children with 
a prenatal diagnosis were born at a lower gestational age (270 days (IQR 264-278) vs 278 
days (IQR 267-286), p<0.001) and at a lower birth weight (3095 grams (IQR 2525-3500) vs 




















437 of the live born children (19.6%, CI 18.0-21.3) died during the first year of 
life at a median age of 15 days (IQR 5-86). Cardiac death was the main cause of mortality and 
accounted for 90.5% (CI 87.8-93.1) of deaths. This proportion changed with the introduction 
of general screening so that cardiac death accounted for 92.8% (CI 89.5-95.1) of deaths before 
the introduction and 85.6% (CI 79.5-91.7) afterwards (p=0.032). Delivery at a tertiary centre 
did not alter overall survival of live born children (Hazard ratio (HR) 0.95 (CI 0.74-1.22), 
p=0.69). However, long distance from referral hospital to tertiary centre increased mortality 
with a HR of 1.07 (CI 1.03-1.11, p<0.001) for every 20 kilometres.  
Survival curves of all-cause mortality before and after the introduction of 
general screening for live born children and TOP combined, as well as for live born children 
only, are shown in Figure 1. Correspondingly, all-cause mortality rates at 30 days and 1 year 
decreased throughout the study (p<0.001 and p<0.001 respectively). Similar results were 
found for cardiac death, whereas there was no development over time in non-cardiac death 
(p=0.49).  
Prematurity was an independent risk factor (HR 9.32 (CI 1.72-50.56), p=0.010). 
Similarly, birth weight was a risk factor as a 500 g decrease in birth weight increased the 
mortality with a HR of 1.38 (CI 1.28-1.49, p<0.001). 
Table 1 shows TOP and 1-year mortality rates for the individual diagnoses. The 
highest rates were found in patients with UVH where 44.8% (CI 41.0-48.7) of all fetuses were 
terminated and 52.6% (CI 47.3-57.8) of live born children died within the first year of life. In 
general, 17.5% (CI 16.0-18.9) of fetuses with major CHD were terminated. This increased 

















2013 (OR 1.15 (CI 1.10-1.20), p<0.001). The increase in TOP rate was not significantly 
affected by the introduction of general screening (OR 0.92 (CI 0.84-1.01), p=0.090). When 
TOPs were included in mortality analyses for major CHD, the combined rate for TOP and 1-
year mortality increased from 30.8% in 1996 to 34.2% in 2004 (OR 1.02 (CI 0.98-1.05), 
p=0.40) reaching 47.8% in 2013 (OR 1.07 (CI 1.03-1.11), p<0.001). The introduction of 
general screening did not significantly alter the combined 1-year mortality and TOP rate (OR 
1.04 (CI 0.98-1.11), p=0.19).  
Figure 2 and Supplementary Table 1 summarise the survival for live born 
children according to time of diagnosis before and after the introduction of general screening. 
Before the introduction there was increased all-cause mortality (HR 2.52 (CI 1.84-3.44), 
p<0.001) and cardiac death (HR 2.40 (CI 1.72-3.33), p<0.001) in children, whose major CHD 
had been diagnosed prenatally. Similarly, in the period with general prenatal screening, there 
was an association between prenatal diagnosis and all-cause mortality (HR 1.94 (CI 1.37-
2.74), p=0.003). The same association was found in cardiac death, however, when we 
adjusted for multiple testing, this association was no longer significant (HR 1.66 (CI 1.13-
1.44), p=0.12). No significant association between prenatal diagnosis and all-cause mortality 
or cardiac death was found when analysing the individual CHDs (Supplementary Table 1). 
Excluding children with associated anomalies did not change the results significantly. 
Among live born children with major CHD, 74.9% (CI 73.1-76.7) underwent 
surgery within the first year of life, and 9.8% died before surgery was possible. Preoperative 
mortality decreased from 14.8% in 1996 to 7.2% in 2004 (OR 0.94 (CI 0.88-0.99), p=0.020) 
and from 8.8% in 2005 to 4.3% in 2013 (OR 0.86 (CI 0.78-0.93), p<0.001), and was not 
affected by the implementation of general screening (p=0.19). Post-operative mortality did 

















0.95 (CI 0.88-1.01), p=0.095)) or the screening period (4.8% in 2005 to 9.1% in 2013 (OR 
0.94 (CI 0.85-1.03), p=0.15)). There was no effect of general prenatal screening on post-
operative mortality (OR 0.98 (CI 086-1.11), p=0.72). Prenatal diagnosis of a major CHD was 
associated with higher risk of preoperative (27.8% (CI 18.3-37.2) vs 10.6% (CI 8.9-12.3), 
p<0.001) and postoperative 30-day mortality (24.2% (CI 13.2-35.2) vs 11.7% (CI 9.6-13.8), 
p=0.008) before general prenatal screening was introduced, but not afterwards (preoperative 
mortality 9.1% (CI 5.5-12.6) vs 5.4% (CI 3.7-7.1), p=0.063, postoperative mortality 8.1% (CI 
4.4-11.8) vs 5.4% (3.5-7.4), p=0.15).  
Non-cardiovascular malformations and chromosomal anomalies were found in 
25.5% (CI 23.9-27.2) and 15.9% (CI 14.5-17.3) of live born children, respectively. The 
presence of a non-cardiovascular malformation was associated with increased prenatal 
detection (34.3% vs 28.9%, p=0.0072), whereas no difference was found in cases with a 
chromosomal anomaly (p=0.46). There were no differences in TOP rates, neither for 
chromosomal anomalies (p=0.081) or non-cardiovascular malformations (p=0.26). All-cause 
mortality did not differ in children with chromosomal anomalies (p=0.57) or non-
cardiovascular malformations (p=0.90). This was also true for cardiac death (p=0.14 and 




LOS in the first year of life did not differ with route of diagnosis before the 
introduction of general prenatal screening (37 days vs 37 days, p=0.17). With general prenatal 

















p<0.001). Complications were found in 21.8% (CI 20.0-23.5) of live born children and the 
frequency increased in the period without general screening (14.2% in 1996 to 22.6% in 2004, 
OR 1.08 (CI 1.03-1.13), p=0.001) and decreased insignificantly in the period with general 
screening (35.3% in 2005 to 28.6% in 2013, OR 0.96 (CI 0.92-1.01), p=0.086). The effect of 
general screening was significant (OR 0.91 (CI 0.84-0.98), p=0.010. There was no significant 
difference between the pre- and postnatally diagnosed children in the occurrence of 
complications before (14.4% vs 17.6%, p=0.52) and after (32.7% vs 26.1%, p=0.12) the 




In this nationwide study on the outcome of major CHD, we evaluated the effect 
of general prenatal screening on mortality and morbidity. To the best of our knowledge, this is 
the largest nationwide, population-based study and the only to compare the outcome in a 
screening group with a non-screening group within the same country. We found that mortality 
among live born children with a major CHD has been decreasing over the past two decades, 
especially after the introduction of general prenatal screening. While a prenatal diagnosis was 
associated with higher cardiac death as well as pre- and postoperative mortality in the period 
without general screening, this association was not significant when general prenatal 
screening was introduced. There was no difference in the risk of complications; however, with 



















Several steps have been taken to improve detection over the past decades; 
ultrasonic machinery and technique have been enhanced and sonographers have undergone 
extensive educational programs. Furthermore, the management of fetuses and children with 
CHD has been centralised and the treatment, including repair techniques, of CHD has been 
improved. As a result, mortality has been reduced substantially
23
. In our study, this was true 
for overall mortality as well as preoperative mortality rates. The reduced mortality may partly 
be due to increased prenatal detection leading to the termination of fetuses with the worst 
prognosis. Correspondingly, when TOP and 1-year mortality rate was considered as a whole, 
the rate increased throughout the study, leading to a decrease in the number of children with 
major CHD reaching their first birthday. Furthermore, there was a significantly stronger 
decrease in mortality after the introduction of general screening.  
4.1.2. 
Prenatal diagnosis and mortality 
The association between prenatal diagnosis and poor prognosis has been 
reported numerous times
1-3,7
, not only in CHD but also with other congenital 
malformations
24,25
. Most recently Wright et al. conducted a study of children with major CHD 
from a single centre. They found an adjusted HR for mortality of 1.5 associated with prenatal 
diagnosis
7
. A population-based study found a HR for mortality of 2.51 associated with a 
prenatal diagnosis in isolated critical CHD, which is comparable to our results
2
.  
This association may be caused by the spectrum of severity with prenatally 
diagnosed major CHD having an a priori more sinister prognosis
3
. The four-chamber view 
tends to mainly detect lesions with poor prognosis
26
; however, with the introduction of 

















defects may be detected in the fetus. Hence, prenatally diagnosed cases become more 
comparable to postnatally diagnosed cases and in our population the association between 
prenatal diagnosis and cardiac death as well as pre- and postoperative mortality disappeared. 
We focused on cardiac death and operative mortality as a prenatal diagnosis will have limited 
effect on other causes of death. 
Prenatal screening for chromosomal anomalies and non-cardiovascular 
malformations has been enhanced during our study and these anomalies are often 
overrepresented in the prenatally diagnosed population
2,5
 as the presence of these anomalies 
indicates a thorough cardiac evaluation. Furthermore, they have been shown to increase 
mortality
5
, thus creating further selection bias. Our findings only ascertained an association 
between non-cardiovascular malformations and prenatal diagnosis; however, the occurrence 
was not associated with increased TOP or mortality.  
Additionally, fetuses with a prenatal diagnosis were born at a lower gestational 
age and with a lower birth weight than patients diagnosed postnatally, which may impact the 
prognosis and outweigh the benefit of prenatal diagnosis
27,28
.  
Fundamentally, selection bias cannot be avoided in pre- and postnatally 
diagnosed groups. An ethically feasible method to overcome this, is a comparison of lesions 
of equal severity e.g. in TOF, where the size of the pulmonary arteries and VSD varies and 
impacts the outcome
29
. Unfortunately, the measurements necessary to identify comparable 
lesions within subgroups were unobtainable in our study. Fuchs et al. conducted a 
retrospective study where echocardiographies were reviewed to ensure comparability between 
the groups and they found improved pre-surgical status and longer catheter intervention-free 



















To reduce selection bias, we compared the non-screening period with the 
screening period, and found that the introduction of general screening had a positive impact 
on mortality related to a prenatal diagnosis, as the association with cardiac death and 
operative mortality was no longer significant in this period. However, the temporal change 
was only significant for preoperative mortality. Nonetheless, the change indicates that, while 
there is still a certain amount of selection bias preventing the change from becoming 
significant, screening all pregnancies ensures that the cases, where detection is of greatest 
importance, are found, and the ones that are missed have a better prognosis.  
A measurable effect on mortality cannot be expected in all lesions, as certain 
defects may remain balanced long enough to allow detection through routine examination. For 
a prenatal diagnosis to make a noteworthy difference on mortality, the CHD must be fatal if 
not diagnosed and treated shortly after birth, as seen in TGA and UVH. All studies that found 
increased mortality in prenatally diagnosed children evaluated the group as a whole. 
However, when addressing a subgroup of lesions some studies have been able to show 
increased survival with a prenatal diagnosis
4,9,10,16,17
. Especially prenatal diagnosis of TGA 
has been shown to be associated with increased survival. The rapid deterioration without 
intervention seen in these patients facilitates the uncovering of an effect and the well-defined 
nature of the condition permits only a very narrow spectrum of severity, making the two 




There was no association between timing of diagnosis and occurrence of 

















inaccuracies, and especially neurocognitive deficits from delayed detection of complex 
lesions, such as TGA, may not be captured and therefore likely underestimate the effect of 
prenatal detection
6
. As mortality decreases, morbidity will increase, as seen in our study. 
Therefore, focus should be placed upon complications in future studies as they become an 
increasingly important endpoint. We did find that patients diagnosed prenatally had a slightly 
longer LOS after the introduction of general screening. The explanation may be that children 
without a prenatal diagnosis may not present themselves with symptoms for several days, thus 
not requiring admission during this time.  
Finally, prenatal detection has several other benefits aside from improving 
prognosis. It enables thorough fetal examination, parental counselling, TOP, genetic testing, 
optimal perinatal management by a multidisciplinary team and allows parents to adjust to the 




Comparing prenatally diagnosed CHD with postnatally diagnosed cases is 
challenging as selection bias is difficult to eliminate and a randomised trial is unethical. The 
introduction of general prenatal screening ensures that the cases where detection is of greatest 
importance are found. Therefore, survival has improved and the association between prenatal 
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Table 1. TOP and 1-year mortality rates in live-born children in Denmark in 1996-2013 
 TOP 1-year 
mortality 
TOP and 1-year 
mortality 
Univentricular hearts  286/638 (44.8) 185/352 (52.6) 471/638 (73.8) 
Congenitally corrected 
transposition of the great 
arteries 
6/51 (11.8) 2/45 (4.4) 8/51 (15.7) 
Truncus arteriosus 18/61 (29.5) 21/43 (48.8) 39/61 (63.9) 
Transposition of the great 
arteries 
16/334 (4.8) 45/318 (14.2) 61/334 (18.3) 
Interrupted aortic arch 6/57 (10.5) 16/51 (31.4) 22/57 (38.6) 
Atrioventricular septal defect 93/461 (20.2) 60/368 (16.3) 153/461 (33.2) 
Double outlet right ventricle 20/139 (14.4) 34/119 (28.6) 54/139 (38.8) 
Coarctation of the aorta 3/490 (0.6) 21/487 (4.3) 24/490 (4.9) 
Ebstein’s anomaly 4/53 (7.5) 6/49 (12.2) 10/53 (18.9) 
Pulmonary atresia with 
ventricular septal defect 
5/86 (5.8) 20/81 (24.7) 25/86 (29.1) 
Pulmonary atresia with intact 
ventricular septum 
3/35 (8.6) 5/32 (15.6) 8/35 (22.9) 
Tetralogy of Fallot 11/290 (3.8) 22/279 (7.9) 33/290 (11.4) 
























Figure 1.  
Survival curves before and after the introduction of general screening from conception (left) 
and from birth (right).  
Figure 2.  
Survival curves for prenatally and postnatally diagnosed live born children before the 
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Survival curves for prenatally and postnatally diagnosed live born children before the 



















 Survival of major congenital heart disease is improving 
 The occurrence of complications is increasing, presumably due to improved survival 
 Prenatal diagnosis of major congenital heart disease is no longer associated with increased 
cardiac death. 
 Great care must be taken when comparing prenatally diagnosed congenital heart disease 
with postnatally diagnosed congenital heart disease 
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